HUTCHMED (China) Limited (HCM) Stock Competitors & Peer Comparison
See (HCM) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| HCM | $10.84 | -6.63% | 1.9B | 4.06 | $2.67 | N/A |
| TAK | $17.15 | +2.51% | 54.6B | 12.34 | $1.39 | +3.68% |
| HLN | $10.10 | -0.10% | 44.5B | 25.28 | $0.40 | +1.92% |
| TEVA | $32.03 | -0.59% | 37.3B | 10.92 | $2.93 | N/A |
| VTRS | $17.29 | -0.23% | 20.1B | 7.06 | $2.45 | +2.77% |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| ELAN | $25.83 | -0.46% | 12.9B | 26.38 | $0.98 | N/A |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
| RDY | $12.60 | -0.79% | 10.5B | 20.66 | $0.61 | +0.51% |
| LNTH | $107.59 | +2.36% | 7B | 18.02 | $5.97 | N/A |
Stock Comparison
HCM vs TAK Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, TAK has a market cap of 54.6B. Regarding current trading prices, HCM is priced at $10.84, while TAK trades at $17.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas TAK's P/E ratio is 12.34. In terms of profitability, HCM's ROE is +0.37%, compared to TAK's ROE of +0.03%. Regarding short-term risk, HCM is less volatile compared to TAK. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TAK's competition here
HCM vs HLN Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, HLN has a market cap of 44.5B. Regarding current trading prices, HCM is priced at $10.84, while HLN trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas HLN's P/E ratio is 25.28. In terms of profitability, HCM's ROE is +0.37%, compared to HLN's ROE of +0.13%. Regarding short-term risk, HCM is less volatile compared to HLN. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check HLN's competition here
HCM vs TEVA Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, TEVA has a market cap of 37.3B. Regarding current trading prices, HCM is priced at $10.84, while TEVA trades at $32.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas TEVA's P/E ratio is 10.92. In terms of profitability, HCM's ROE is +0.37%, compared to TEVA's ROE of +0.21%. Regarding short-term risk, HCM is less volatile compared to TEVA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TEVA's competition here
HCM vs VTRS Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, VTRS has a market cap of 20.1B. Regarding current trading prices, HCM is priced at $10.84, while VTRS trades at $17.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas VTRS's P/E ratio is 7.06. In terms of profitability, HCM's ROE is +0.37%, compared to VTRS's ROE of -0.02%. Regarding short-term risk, HCM is less volatile compared to VTRS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check VTRS's competition here
HCM vs ITCI Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, HCM is priced at $10.84, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ITCI's P/E ratio is -180.64. In terms of profitability, HCM's ROE is +0.37%, compared to ITCI's ROE of -0.09%. Regarding short-term risk, HCM is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ITCI's competition here
HCM vs ELAN Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ELAN has a market cap of 12.9B. Regarding current trading prices, HCM is priced at $10.84, while ELAN trades at $25.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ELAN's P/E ratio is 26.38. In terms of profitability, HCM's ROE is +0.37%, compared to ELAN's ROE of -0.04%. Regarding short-term risk, HCM is less volatile compared to ELAN. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ELAN's competition here
HCM vs CTLT Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, HCM is priced at $10.84, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas CTLT's P/E ratio is -27.84. In terms of profitability, HCM's ROE is +0.37%, compared to CTLT's ROE of -0.25%. Regarding short-term risk, HCM is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check CTLT's competition here
HCM vs RDY Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, RDY has a market cap of 10.5B. Regarding current trading prices, HCM is priced at $10.84, while RDY trades at $12.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas RDY's P/E ratio is 20.66. In terms of profitability, HCM's ROE is +0.37%, compared to RDY's ROE of +0.12%. Regarding short-term risk, HCM is less volatile compared to RDY. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RDY's competition here
HCM vs LNTH Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, LNTH has a market cap of 7B. Regarding current trading prices, HCM is priced at $10.84, while LNTH trades at $107.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas LNTH's P/E ratio is 18.02. In terms of profitability, HCM's ROE is +0.37%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, HCM is less volatile compared to LNTH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LNTH's competition here
HCM vs AMRX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, AMRX has a market cap of 5.7B. Regarding current trading prices, HCM is priced at $10.84, while AMRX trades at $17.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas AMRX's P/E ratio is 19.83. In terms of profitability, HCM's ROE is +0.37%, compared to AMRX's ROE of -1.45%. Regarding short-term risk, HCM is less volatile compared to AMRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AMRX's competition here
HCM vs INDV Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, INDV has a market cap of 5.1B. Regarding current trading prices, HCM is priced at $10.84, while INDV trades at $40.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas INDV's P/E ratio is 13.49. In terms of profitability, HCM's ROE is +0.37%, compared to INDV's ROE of -1.42%. Regarding short-term risk, HCM is less volatile compared to INDV. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check INDV's competition here
HCM vs SUPN Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, SUPN has a market cap of 2.8B. Regarding current trading prices, HCM is priced at $10.84, while SUPN trades at $48.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas SUPN's P/E ratio is 14.01. In terms of profitability, HCM's ROE is +0.37%, compared to SUPN's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to SUPN. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SUPN's competition here
HCM vs RGC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, RGC has a market cap of 2.5B. Regarding current trading prices, HCM is priced at $10.84, while RGC trades at $5.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas RGC's P/E ratio is -353.52. In terms of profitability, HCM's ROE is +0.37%, compared to RGC's ROE of -2.32%. Regarding short-term risk, HCM is less volatile compared to RGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RGC's competition here
HCM vs DCPH Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, HCM is priced at $10.84, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas DCPH's P/E ratio is -11.58. In terms of profitability, HCM's ROE is +0.37%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, HCM is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check DCPH's competition here
HCM vs AVDL Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, AVDL has a market cap of 2.1B. Regarding current trading prices, HCM is priced at $10.84, while AVDL trades at $21.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas AVDL's P/E ratio is -1082.00. In terms of profitability, HCM's ROE is +0.37%, compared to AVDL's ROE of +0.05%. Regarding short-term risk, HCM is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check AVDL's competition here
HCM vs EMBCV Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, HCM is priced at $10.84, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas EMBCV's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.37%, compared to EMBCV's ROE of -0.23%. Regarding short-term risk, HCM is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EMBCV's competition here
HCM vs DVAX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, DVAX has a market cap of 1.8B. Regarding current trading prices, HCM is priced at $10.84, while DVAX trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas DVAX's P/E ratio is -41.89. In terms of profitability, HCM's ROE is +0.37%, compared to DVAX's ROE of -0.10%. Regarding short-term risk, HCM is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check DVAX's competition here
HCM vs BHC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, BHC has a market cap of 1.8B. Regarding current trading prices, HCM is priced at $10.84, while BHC trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas BHC's P/E ratio is 1.23. In terms of profitability, HCM's ROE is +0.37%, compared to BHC's ROE of +1.21%. Regarding short-term risk, HCM is less volatile compared to BHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BHC's competition here
HCM vs ANIP Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ANIP has a market cap of 1.8B. Regarding current trading prices, HCM is priced at $10.84, while ANIP trades at $79.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ANIP's P/E ratio is 9.64. In terms of profitability, HCM's ROE is +0.37%, compared to ANIP's ROE of +0.17%. Regarding short-term risk, HCM is less volatile compared to ANIP. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ANIP's competition here
HCM vs HROW Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, HROW has a market cap of 1.7B. Regarding current trading prices, HCM is priced at $10.84, while HROW trades at $46.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas HROW's P/E ratio is 498.67. In terms of profitability, HCM's ROE is +0.37%, compared to HROW's ROE of -0.34%. Regarding short-term risk, HCM is less volatile compared to HROW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check HROW's competition here
HCM vs TARO Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, HCM is priced at $10.84, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas TARO's P/E ratio is 30.05. In terms of profitability, HCM's ROE is +0.37%, compared to TARO's ROE of +0.03%. Regarding short-term risk, HCM is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check TARO's competition here
HCM vs PRGO Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, PRGO has a market cap of 1.5B. Regarding current trading prices, HCM is priced at $10.84, while PRGO trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas PRGO's P/E ratio is 4.17. In terms of profitability, HCM's ROE is +0.37%, compared to PRGO's ROE of -0.51%. Regarding short-term risk, HCM is less volatile compared to PRGO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PRGO's competition here
HCM vs PAHC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, PAHC has a market cap of 1.4B. Regarding current trading prices, HCM is priced at $10.84, while PAHC trades at $33.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas PAHC's P/E ratio is 11.37. In terms of profitability, HCM's ROE is +0.37%, compared to PAHC's ROE of +0.29%. Regarding short-term risk, HCM is less volatile compared to PAHC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PAHC's competition here
HCM vs ALVO Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ALVO has a market cap of 1.2B. Regarding current trading prices, HCM is priced at $10.84, while ALVO trades at $3.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ALVO's P/E ratio is -10.18. In terms of profitability, HCM's ROE is +0.37%, compared to ALVO's ROE of +0.35%. Regarding short-term risk, HCM is less volatile compared to ALVO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ALVO's competition here
HCM vs COLL Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, COLL has a market cap of 1.2B. Regarding current trading prices, HCM is priced at $10.84, while COLL trades at $36.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas COLL's P/E ratio is 4.67. In terms of profitability, HCM's ROE is +0.37%, compared to COLL's ROE of +0.27%. Regarding short-term risk, HCM is less volatile compared to COLL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check COLL's competition here
HCM vs ETON Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ETON has a market cap of 1.2B. Regarding current trading prices, HCM is priced at $10.84, while ETON trades at $42.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ETON's P/E ratio is -604.57. In terms of profitability, HCM's ROE is +0.37%, compared to ETON's ROE of -0.06%. Regarding short-term risk, HCM is less volatile compared to ETON. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ETON's competition here
HCM vs ALVOW Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ALVOW has a market cap of 1.1B. Regarding current trading prices, HCM is priced at $10.84, while ALVOW trades at $0.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ALVOW's P/E ratio is 25.47. In terms of profitability, HCM's ROE is +0.37%, compared to ALVOW's ROE of +0.35%. Regarding short-term risk, HCM is more volatile compared to ALVOW. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ALVOW's competition here
HCM vs CRON Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, CRON has a market cap of 1B. Regarding current trading prices, HCM is priced at $10.84, while CRON trades at $2.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas CRON's P/E ratio is -112.96. In terms of profitability, HCM's ROE is +0.37%, compared to CRON's ROE of -0.00%. Regarding short-term risk, HCM is less volatile compared to CRON. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CRON's competition here
HCM vs PCRX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, PCRX has a market cap of 1B. Regarding current trading prices, HCM is priced at $10.84, while PCRX trades at $25.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas PCRX's P/E ratio is 9.81. In terms of profitability, HCM's ROE is +0.37%, compared to PCRX's ROE of +0.01%. Regarding short-term risk, HCM is less volatile compared to PCRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PCRX's competition here
HCM vs PETQ Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, HCM is priced at $10.84, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas PETQ's P/E ratio is 83.73. In terms of profitability, HCM's ROE is +0.37%, compared to PETQ's ROE of +0.01%. Regarding short-term risk, HCM is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check PETQ's competition here
HCM vs AMPH Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, AMPH has a market cap of 870.6M. Regarding current trading prices, HCM is priced at $10.84, while AMPH trades at $19.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas AMPH's P/E ratio is 6.74. In terms of profitability, HCM's ROE is +0.37%, compared to AMPH's ROE of +0.10%. Regarding short-term risk, HCM is less volatile compared to AMPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AMPH's competition here
HCM vs EVO Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, EVO has a market cap of 696.2M. Regarding current trading prices, HCM is priced at $10.84, while EVO trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas EVO's P/E ratio is -2.77. In terms of profitability, HCM's ROE is +0.37%, compared to EVO's ROE of -0.24%. Regarding short-term risk, HCM is less volatile compared to EVO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EVO's competition here
HCM vs IRWD Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, IRWD has a market cap of 637.1M. Regarding current trading prices, HCM is priced at $10.84, while IRWD trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas IRWD's P/E ratio is 6.34. In terms of profitability, HCM's ROE is +0.37%, compared to IRWD's ROE of -0.39%. Regarding short-term risk, HCM is less volatile compared to IRWD. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check IRWD's competition here
HCM vs BDSI Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, HCM is priced at $10.84, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas BDSI's P/E ratio is 6.82. In terms of profitability, HCM's ROE is +0.37%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, HCM is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check BDSI's competition here
HCM vs TLRY Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, TLRY has a market cap of 516M. Regarding current trading prices, HCM is priced at $10.84, while TLRY trades at $4.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas TLRY's P/E ratio is -6.78. In terms of profitability, HCM's ROE is +0.37%, compared to TLRY's ROE of -0.93%. Regarding short-term risk, HCM is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TLRY's competition here
HCM vs AQST Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, AQST has a market cap of 409.1M. Regarding current trading prices, HCM is priced at $10.84, while AQST trades at $4.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas AQST's P/E ratio is -6.75. In terms of profitability, HCM's ROE is +0.37%, compared to AQST's ROE of +1.91%. Regarding short-term risk, HCM is less volatile compared to AQST. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AQST's competition here
HCM vs KMDA Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, KMDA has a market cap of 406.7M. Regarding current trading prices, HCM is priced at $10.84, while KMDA trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas KMDA's P/E ratio is 20.14. In terms of profitability, HCM's ROE is +0.37%, compared to KMDA's ROE of +0.08%. Regarding short-term risk, HCM is less volatile compared to KMDA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check KMDA's competition here
HCM vs CGC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, CGC has a market cap of 396.8M. Regarding current trading prices, HCM is priced at $10.84, while CGC trades at $0.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas CGC's P/E ratio is -0.57. In terms of profitability, HCM's ROE is +0.37%, compared to CGC's ROE of -0.39%. Regarding short-term risk, HCM is less volatile compared to CGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CGC's competition here
HCM vs EOLS Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, EOLS has a market cap of 377.3M. Regarding current trading prices, HCM is priced at $10.84, while EOLS trades at $5.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas EOLS's P/E ratio is -13.15. In terms of profitability, HCM's ROE is +0.37%, compared to EOLS's ROE of +1.75%. Regarding short-term risk, HCM is less volatile compared to EOLS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EOLS's competition here
HCM vs ORGO Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ORGO has a market cap of 337.1M. Regarding current trading prices, HCM is priced at $10.84, while ORGO trades at $2.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ORGO's P/E ratio is 87.33. In terms of profitability, HCM's ROE is +0.37%, compared to ORGO's ROE of -0.00%. Regarding short-term risk, HCM is less volatile compared to ORGO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ORGO's competition here
HCM vs SNDL Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, SNDL has a market cap of 333.2M. Regarding current trading prices, HCM is priced at $10.84, while SNDL trades at $1.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas SNDL's P/E ratio is -42.67. In terms of profitability, HCM's ROE is +0.37%, compared to SNDL's ROE of -0.01%. Regarding short-term risk, HCM is less volatile compared to SNDL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SNDL's competition here
HCM vs ALIM Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, HCM is priced at $10.84, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ALIM's P/E ratio is 5.28. In terms of profitability, HCM's ROE is +0.37%, compared to ALIM's ROE of -1.59%. Regarding short-term risk, HCM is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ALIM's competition here
HCM vs TKNO Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, TKNO has a market cap of 290.6M. Regarding current trading prices, HCM is priced at $10.84, while TKNO trades at $5.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas TKNO's P/E ratio is -16.94. In terms of profitability, HCM's ROE is +0.37%, compared to TKNO's ROE of -0.24%. Regarding short-term risk, HCM is less volatile compared to TKNO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TKNO's competition here
HCM vs LNDC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, HCM is priced at $10.84, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas LNDC's P/E ratio is -4.04. In terms of profitability, HCM's ROE is +0.37%, compared to LNDC's ROE of -9.05%. Regarding short-term risk, HCM is less volatile compared to LNDC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LNDC's competition here
HCM vs SIGA Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, SIGA has a market cap of 246.7M. Regarding current trading prices, HCM is priced at $10.84, while SIGA trades at $3.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas SIGA's P/E ratio is 12.74. In terms of profitability, HCM's ROE is +0.37%, compared to SIGA's ROE of +0.11%. Regarding short-term risk, HCM is less volatile compared to SIGA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SIGA's competition here
HCM vs TYHT Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, HCM is priced at $10.84, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas TYHT's P/E ratio is -1.61. In terms of profitability, HCM's ROE is +0.37%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, HCM is less volatile compared to TYHT. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TYHT's competition here
HCM vs DERM Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, DERM has a market cap of 197.1M. Regarding current trading prices, HCM is priced at $10.84, while DERM trades at $7.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas DERM's P/E ratio is -19.35. In terms of profitability, HCM's ROE is +0.37%, compared to DERM's ROE of -0.36%. Regarding short-term risk, HCM is less volatile compared to DERM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check DERM's competition here
HCM vs EMBC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, EMBC has a market cap of 192.8M. Regarding current trading prices, HCM is priced at $10.84, while EMBC trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas EMBC's P/E ratio is 1.25. In terms of profitability, HCM's ROE is +0.37%, compared to EMBC's ROE of -0.17%. Regarding short-term risk, HCM is less volatile compared to EMBC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check EMBC's competition here
HCM vs REPH Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, HCM is priced at $10.84, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas REPH's P/E ratio is -8.04. In terms of profitability, HCM's ROE is +0.37%, compared to REPH's ROE of -0.22%. Regarding short-term risk, HCM is less volatile compared to REPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check REPH's competition here
HCM vs LFCR Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, LFCR has a market cap of 175.5M. Regarding current trading prices, HCM is priced at $10.84, while LFCR trades at $4.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas LFCR's P/E ratio is -4.78. In terms of profitability, HCM's ROE is +0.37%, compared to LFCR's ROE of -1.76%. Regarding short-term risk, HCM is less volatile compared to LFCR. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LFCR's competition here
HCM vs ACB Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ACB has a market cap of 162.9M. Regarding current trading prices, HCM is priced at $10.84, while ACB trades at $2.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ACB's P/E ratio is 43.83. In terms of profitability, HCM's ROE is +0.37%, compared to ACB's ROE of -0.14%. Regarding short-term risk, HCM is less volatile compared to ACB. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ACB's competition here
HCM vs THTX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, THTX has a market cap of 155.9M. Regarding current trading prices, HCM is priced at $10.84, while THTX trades at $3.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas THTX's P/E ratio is -28.83. In terms of profitability, HCM's ROE is +0.37%, compared to THTX's ROE of +0.17%. Regarding short-term risk, HCM is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check THTX's competition here
HCM vs ASRT Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ASRT has a market cap of 151.9M. Regarding current trading prices, HCM is priced at $10.84, while ASRT trades at $23.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ASRT's P/E ratio is -7.10. In terms of profitability, HCM's ROE is +0.37%, compared to ASRT's ROE of -0.39%. Regarding short-term risk, HCM is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ASRT's competition here
HCM vs CRDL Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, CRDL has a market cap of 139.5M. Regarding current trading prices, HCM is priced at $10.84, while CRDL trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas CRDL's P/E ratio is -4.31. In terms of profitability, HCM's ROE is +0.37%, compared to CRDL's ROE of -2.29%. Regarding short-term risk, HCM is less volatile compared to CRDL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CRDL's competition here
HCM vs OGI Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, OGI has a market cap of 126.7M. Regarding current trading prices, HCM is priced at $10.84, while OGI trades at $0.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas OGI's P/E ratio is -3.46. In terms of profitability, HCM's ROE is +0.37%, compared to OGI's ROE of -0.07%. Regarding short-term risk, HCM is less volatile compared to OGI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check OGI's competition here
HCM vs SCTL Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, HCM is priced at $10.84, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas SCTL's P/E ratio is -7.86. In terms of profitability, HCM's ROE is +0.37%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, HCM is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check SCTL's competition here
HCM vs CPIX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, CPIX has a market cap of 102.5M. Regarding current trading prices, HCM is priced at $10.84, while CPIX trades at $6.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas CPIX's P/E ratio is -38.00. In terms of profitability, HCM's ROE is +0.37%, compared to CPIX's ROE of -0.29%. Regarding short-term risk, HCM is less volatile compared to CPIX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CPIX's competition here
HCM vs PROC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, PROC has a market cap of 102.1M. Regarding current trading prices, HCM is priced at $10.84, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas PROC's P/E ratio is 1.53. In terms of profitability, HCM's ROE is +0.37%, compared to PROC's ROE of -2.22%. Regarding short-term risk, HCM is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check PROC's competition here
HCM vs OPTN Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, HCM is priced at $10.84, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas OPTN's P/E ratio is -4.42. In terms of profitability, HCM's ROE is +0.37%, compared to OPTN's ROE of +0.34%. Regarding short-term risk, HCM is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check OPTN's competition here
HCM vs ZOM Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, HCM is priced at $10.84, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ZOM's P/E ratio is -1.62. In terms of profitability, HCM's ROE is +0.37%, compared to ZOM's ROE of -0.19%. Regarding short-term risk, HCM is less volatile compared to ZOM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZOM's competition here
HCM vs GRVI Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, HCM is priced at $10.84, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas GRVI's P/E ratio is 26.05. In terms of profitability, HCM's ROE is +0.37%, compared to GRVI's ROE of -2.54%. Regarding short-term risk, HCM is less volatile compared to GRVI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check GRVI's competition here
HCM vs ZYNE Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, HCM is priced at $10.84, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, HCM's ROE is +0.37%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, HCM is less volatile compared to ZYNE. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZYNE's competition here
HCM vs SSIC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, HCM is priced at $10.84, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas SSIC's P/E ratio is 11.93. In terms of profitability, HCM's ROE is +0.37%, compared to SSIC's ROE of +0.00%. Regarding short-term risk, HCM is less volatile compared to SSIC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SSIC's competition here
HCM vs VLNS Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, HCM is priced at $10.84, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas VLNS's P/E ratio is -1.03. In terms of profitability, HCM's ROE is +0.37%, compared to VLNS's ROE of N/A. Regarding short-term risk, HCM is less volatile compared to VLNS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check VLNS's competition here
HCM vs DRRX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, DRRX has a market cap of 59.3M. Regarding current trading prices, HCM is priced at $10.84, while DRRX trades at $1.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas DRRX's P/E ratio is -4.44. In terms of profitability, HCM's ROE is +0.37%, compared to DRRX's ROE of -1.40%. Regarding short-term risk, HCM is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check DRRX's competition here
HCM vs BGM Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, BGM has a market cap of 56.5M. Regarding current trading prices, HCM is priced at $10.84, while BGM trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas BGM's P/E ratio is -0.97. In terms of profitability, HCM's ROE is +0.37%, compared to BGM's ROE of -0.03%. Regarding short-term risk, HCM is less volatile compared to BGM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BGM's competition here
HCM vs INCR Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, INCR has a market cap of 53.7M. Regarding current trading prices, HCM is priced at $10.84, while INCR trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas INCR's P/E ratio is -2.17. In terms of profitability, HCM's ROE is +0.37%, compared to INCR's ROE of -0.09%. Regarding short-term risk, HCM is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check INCR's competition here
HCM vs JUPW Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, HCM is priced at $10.84, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas JUPW's P/E ratio is -2.41. In terms of profitability, HCM's ROE is +0.37%, compared to JUPW's ROE of -1.94%. Regarding short-term risk, HCM is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check JUPW's competition here
HCM vs QLI Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, HCM is priced at $10.84, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas QLI's P/E ratio is -4.92. In terms of profitability, HCM's ROE is +0.37%, compared to QLI's ROE of -0.16%. Regarding short-term risk, HCM is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check QLI's competition here
HCM vs IXHL Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, IXHL has a market cap of 37.7M. Regarding current trading prices, HCM is priced at $10.84, while IXHL trades at $3.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas IXHL's P/E ratio is -4.60. In terms of profitability, HCM's ROE is +0.37%, compared to IXHL's ROE of -0.92%. Regarding short-term risk, HCM is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check IXHL's competition here
HCM vs ZYBT Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ZYBT has a market cap of 33.1M. Regarding current trading prices, HCM is priced at $10.84, while ZYBT trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ZYBT's P/E ratio is -3.17. In terms of profitability, HCM's ROE is +0.37%, compared to ZYBT's ROE of -0.27%. Regarding short-term risk, HCM is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ZYBT's competition here
HCM vs HEXO Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, HCM is priced at $10.84, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas HEXO's P/E ratio is -0.26. In terms of profitability, HCM's ROE is +0.37%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, HCM is less volatile compared to HEXO. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check HEXO's competition here
HCM vs TLPH Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, TLPH has a market cap of 27.2M. Regarding current trading prices, HCM is priced at $10.84, while TLPH trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas TLPH's P/E ratio is -4.27. In terms of profitability, HCM's ROE is +0.37%, compared to TLPH's ROE of -0.93%. Regarding short-term risk, HCM is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TLPH's competition here
HCM vs RMTI Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, RMTI has a market cap of 24.2M. Regarding current trading prices, HCM is priced at $10.84, while RMTI trades at $6.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas RMTI's P/E ratio is -5.83. In terms of profitability, HCM's ROE is +0.37%, compared to RMTI's ROE of -0.15%. Regarding short-term risk, HCM is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RMTI's competition here
HCM vs TXMD Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, TXMD has a market cap of 23.8M. Regarding current trading prices, HCM is priced at $10.84, while TXMD trades at $2.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas TXMD's P/E ratio is 104.94. In terms of profitability, HCM's ROE is +0.37%, compared to TXMD's ROE of +0.01%. Regarding short-term risk, HCM is less volatile compared to TXMD. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check TXMD's competition here
HCM vs CYTH Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, HCM is priced at $10.84, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas CYTH's P/E ratio is -0.80. In terms of profitability, HCM's ROE is +0.37%, compared to CYTH's ROE of -7.30%. Regarding short-term risk, HCM is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check CYTH's competition here
HCM vs EVOK Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, EVOK has a market cap of 18.9M. Regarding current trading prices, HCM is priced at $10.84, while EVOK trades at $11.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas EVOK's P/E ratio is -7.97. In terms of profitability, HCM's ROE is +0.37%, compared to EVOK's ROE of -0.89%. Regarding short-term risk, HCM is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check EVOK's competition here
HCM vs AYTU Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, AYTU has a market cap of 17.4M. Regarding current trading prices, HCM is priced at $10.84, while AYTU trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas AYTU's P/E ratio is -1.12. In terms of profitability, HCM's ROE is +0.37%, compared to AYTU's ROE of -1.49%. Regarding short-term risk, HCM is less volatile compared to AYTU. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AYTU's competition here
HCM vs OPTH Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, OPTH has a market cap of 16.1M. Regarding current trading prices, HCM is priced at $10.84, while OPTH trades at $5.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas OPTH's P/E ratio is -18.34. In terms of profitability, HCM's ROE is +0.37%, compared to OPTH's ROE of -0.94%. Regarding short-term risk, HCM is less volatile compared to OPTH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check OPTH's competition here
HCM vs ACRX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, HCM is priced at $10.84, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ACRX's P/E ratio is -0.31. In terms of profitability, HCM's ROE is +0.37%, compared to ACRX's ROE of -0.93%. Regarding short-term risk, HCM is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ACRX's competition here
HCM vs COSM Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, COSM has a market cap of 14.6M. Regarding current trading prices, HCM is priced at $10.84, while COSM trades at $0.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas COSM's P/E ratio is -0.38. In terms of profitability, HCM's ROE is +0.37%, compared to COSM's ROE of -0.96%. Regarding short-term risk, HCM is less volatile compared to COSM. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check COSM's competition here
HCM vs AGRX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, HCM is priced at $10.84, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas AGRX's P/E ratio is -0.89. In terms of profitability, HCM's ROE is +0.37%, compared to AGRX's ROE of +1.32%. Regarding short-term risk, HCM is less volatile compared to AGRX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check AGRX's competition here
HCM vs BFRIW Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, BFRIW has a market cap of 9.6M. Regarding current trading prices, HCM is priced at $10.84, while BFRIW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas BFRIW's P/E ratio is -0.02. In terms of profitability, HCM's ROE is +0.37%, compared to BFRIW's ROE of -4.77%. Regarding short-term risk, HCM is less volatile compared to BFRIW. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check BFRIW's competition here
HCM vs NLTX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, HCM is priced at $10.84, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas NLTX's P/E ratio is -0.28. In terms of profitability, HCM's ROE is +0.37%, compared to NLTX's ROE of -0.38%. Regarding short-term risk, HCM is less volatile compared to NLTX. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check NLTX's competition here
HCM vs LCI Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, HCM is priced at $10.84, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas LCI's P/E ratio is -0.04. In terms of profitability, HCM's ROE is +0.37%, compared to LCI's ROE of +1.66%. Regarding short-term risk, HCM is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check LCI's competition here
HCM vs ADMP Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ADMP has a market cap of 7.3M. Regarding current trading prices, HCM is priced at $10.84, while ADMP trades at $0.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ADMP's P/E ratio is -0.08. In terms of profitability, HCM's ROE is +0.37%, compared to ADMP's ROE of -2.09%. Regarding short-term risk, HCM is less volatile compared to ADMP. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check ADMP's competition here
HCM vs YCBD Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, YCBD has a market cap of 5.9M. Regarding current trading prices, HCM is priced at $10.84, while YCBD trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas YCBD's P/E ratio is -1.38. In terms of profitability, HCM's ROE is +0.37%, compared to YCBD's ROE of -0.34%. Regarding short-term risk, HCM is less volatile compared to YCBD. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check YCBD's competition here
HCM vs GELS Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, GELS has a market cap of 5.6M. Regarding current trading prices, HCM is priced at $10.84, while GELS trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas GELS's P/E ratio is -1.21. In terms of profitability, HCM's ROE is +0.37%, compared to GELS's ROE of -0.25%. Regarding short-term risk, HCM is less volatile compared to GELS. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check GELS's competition here
HCM vs MNK Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, MNK has a market cap of 4.5M. Regarding current trading prices, HCM is priced at $10.84, while MNK trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas MNK's P/E ratio is -0.44. In terms of profitability, HCM's ROE is +0.37%, compared to MNK's ROE of -0.26%. Regarding short-term risk, HCM is less volatile compared to MNK. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check MNK's competition here
HCM vs FLGC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, FLGC has a market cap of 4.2M. Regarding current trading prices, HCM is priced at $10.84, while FLGC trades at $7.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas FLGC's P/E ratio is -0.19. In terms of profitability, HCM's ROE is +0.37%, compared to FLGC's ROE of -2.70%. Regarding short-term risk, HCM is less volatile compared to FLGC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check FLGC's competition here
HCM vs CPHI Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, CPHI has a market cap of 3.3M. Regarding current trading prices, HCM is priced at $10.84, while CPHI trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas CPHI's P/E ratio is -1.64. In terms of profitability, HCM's ROE is +0.37%, compared to CPHI's ROE of -0.19%. Regarding short-term risk, HCM is less volatile compared to CPHI. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check CPHI's competition here
HCM vs UPC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, UPC has a market cap of 2.8M. Regarding current trading prices, HCM is priced at $10.84, while UPC trades at $4.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas UPC's P/E ratio is -0.55. In terms of profitability, HCM's ROE is +0.37%, compared to UPC's ROE of -0.07%. Regarding short-term risk, HCM is less volatile compared to UPC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check UPC's competition here
HCM vs PLXP Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, PLXP has a market cap of 2.5M. Regarding current trading prices, HCM is priced at $10.84, while PLXP trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas PLXP's P/E ratio is -0.22. In terms of profitability, HCM's ROE is +0.37%, compared to PLXP's ROE of -1.66%. Regarding short-term risk, HCM is less volatile compared to PLXP. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check PLXP's competition here
HCM vs ATNX Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, ATNX has a market cap of 2.3M. Regarding current trading prices, HCM is priced at $10.84, while ATNX trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas ATNX's P/E ratio is -0.02. In terms of profitability, HCM's ROE is +0.37%, compared to ATNX's ROE of +0.22%. Regarding short-term risk, HCM is more volatile compared to ATNX. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check ATNX's competition here
HCM vs RDHL Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, RDHL has a market cap of 2.2M. Regarding current trading prices, HCM is priced at $10.84, while RDHL trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas RDHL's P/E ratio is 0.14. In terms of profitability, HCM's ROE is +0.37%, compared to RDHL's ROE of +57.40%. Regarding short-term risk, HCM is less volatile compared to RDHL. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check RDHL's competition here
HCM vs SNOA Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, SNOA has a market cap of 2M. Regarding current trading prices, HCM is priced at $10.84, while SNOA trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas SNOA's P/E ratio is -1.29. In terms of profitability, HCM's ROE is +0.37%, compared to SNOA's ROE of -0.88%. Regarding short-term risk, HCM is less volatile compared to SNOA. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SNOA's competition here
HCM vs PROCW Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, PROCW has a market cap of 2M. Regarding current trading prices, HCM is priced at $10.84, while PROCW trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas PROCW's P/E ratio is N/A. In terms of profitability, HCM's ROE is +0.37%, compared to PROCW's ROE of -2.22%. Regarding short-term risk, HCM is more volatile compared to PROCW. This indicates potentially higher risk in terms of short-term price fluctuations for HCM.Check PROCW's competition here
HCM vs SHPH Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, SHPH has a market cap of 1.8M. Regarding current trading prices, HCM is priced at $10.84, while SHPH trades at $3.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas SHPH's P/E ratio is -0.15. In terms of profitability, HCM's ROE is +0.37%, compared to SHPH's ROE of -4.08%. Regarding short-term risk, HCM is less volatile compared to SHPH. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SHPH's competition here
HCM vs SXTC Comparison July 2026
HCM plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, HCM stands at 1.9B. In comparison, SXTC has a market cap of 1.7M. Regarding current trading prices, HCM is priced at $10.84, while SXTC trades at $2.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
HCM currently has a P/E ratio of 4.06, whereas SXTC's P/E ratio is 0.90. In terms of profitability, HCM's ROE is +0.37%, compared to SXTC's ROE of -0.31%. Regarding short-term risk, HCM is less volatile compared to SXTC. This indicates potentially lower risk in terms of short-term price fluctuations for HCM.Check SXTC's competition here